Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Topiramate Tablets Dominate November Rises In UK

Pricewatch UK – November 2021

Executive Summary

Topiramate tablets took four places in our table of average UK generic price rises for November 2021, as prices as much as trebled for the epilepsy treatment. However, one product ranked even higher with a 231% average price rise.

You may also be interested in...



Differing Dynamics Demonstrated In UK As Duo Double In October

Two generics saw their average UK trade prices almost double in October for very different reasons, according to the latest pricing information from market researcher WaveData.

Lupin Expects Exeltis Partnership To Boost Solosec

Lupin is hoping that a newly-struck partnership with women’s health specialist Exeltis will improve the fortunes of its Solosec (secnidazole) bacterial vaginosis and trichomoniasis treatment in the US.

Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout

Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.

Topics

UsernamePublicRestriction

Register

GB151488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel